Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I8QJ
|
|||
| Former ID |
DNCL002640
|
|||
| Drug Name |
Ranpirnase
|
|||
| Indication | Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 2 | [1] | |
| Company |
Tamir Biotechnology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ribonuclease (RNase) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01184287) A Study Of Ranpirnase(Onconase) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.